



University of California
San Francisco

UCSF Urologic Oncology Database (UODB) Prostate, Renal, and Bladder

Current Publications

Prepared by:

UCSF Department of Urology
Genitourinary Cancer Epidemiology and
Population Science (G-CEPS) Group

UCSF Helen Diller Family
Comprehensive
Cancer Center



Project Staff:

Peter R. Carroll, M.D., M.P.H.
Professor and Chair
UCSF Department of Urology,
Ken and Donna Derr-Chevron
Distinguished Professor
Principal Investigator – UODB
Tel: (415) 353-7098
Email: pccarroll@urology.ucsf.edu

June M. Chan, Sc.D.
Associate Professor, Epidemiology &
Biostatistics and Urology
Steven and Christine Burd-
Safeway Distinguished Professor
Co-Principal Investigator - UODB
Tel: (415) 514-4923
Email: jchan@urology.ucsf.edu

Matthew R. Cooperberg, M.D., M.P.H.
Assistant Professor
UCSF Department of Urology
Co-Investigator - UODB
Tel: (415) 885-3660
Email: mcooperberg@urology.ucsf.edu

Jeanette M. Broering, R.N., M.S., M.P.H.
Director, Data Operations
UCSF Department of Urology
Co-Investigator - UODB
Tel: (415) 514-0203
Email: jenny.broering@ucsf.edu

Statistical Programmer Staff:

Janet Cowan, M.A.
Tel: (415) 353-7424
Email: jcowan@urology.ucsf.edu

Alan Paciorek, B.S.
Tel: (415) 514-4925
Email: apaciorek@urology.ucsf.edu

Mailing Address:

UCSF – Laurel Heights Campus
3333 California Street, Suite 282
San Francisco, California 94118-1944
Telephone: (415) 514-0201
Facsimile: (415) 514-0210
Toll Free: (800) 526-4433

2003

1. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. *J Urol*. 2003 Aug;170(2 Pt 1):512-5. [PMID: 12853811](#)

2004

2. Anast JW, Stoller ML, Meng MV, Master VA, Mitchell JA, Bassett WW, Kane CJ. Difference in complications and outcomes for obese patients undergoing laparoscopic radical, partial or simple nephrectomy. *J Urol*. 2004 Dec;172(6 Pt 1):2287-91. [PMID: 15538250](#)

3. Kane CJ, Mitchell JA, Meng MV, Anast J, Carroll PR, Stoller ML. Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal function outcomes. *Urology*. 2004;63(2):241-6. [PMID: 14972462](#)

2005

4. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. *J Urol*. 2005 Nov;174(5):1789-93; discussion 1793. [PMID: 16217288](#)

5. Master VA, Gottschalk AR, Kane CJ, Carroll PR. Management of isolated renal fossa recurrence following radical nephrectomy. *J Urol*. 2005 Aug;174(2):473-7. Discussion 477. [PMID: 16006867](#)

2006

6. Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. *J Endourol*. 2006 Jul;20(7):504-8. [PMID: 16859465](#)

2008

7. Dall'Era MA, Konety BR. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. *Nat Clin Pract Urol*. 2008 May;5(5):277-83. [PMID: 18285752](#)

8. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. *Cancer*. 2008 Jun 15;112(12):2664-70; comment 2631-4. [PMID: 18433013](#)

9. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. *Cancer*. 2008 Apr 15;112(8):1650-9. [PMID: 18306379](#)

2009

10. Conti SL, Dall'Era MA, Fradet V, Cowan JE, Simko J, Carroll PR. Pathologic outcomes in men meeting criteria for active surveillance of prostate cancer. *J Urol*. 2009 Apr;181(4):1628-33; discussion 1633-4. [PMID: 19233388](#)

Comment in: *J Urol*. 2009 Apr;181(4):1534-5.

11. Dall'Era MA, Carroll PR. Outcomes and follow-up strategies for patients on active surveillance. *Curr Opin Urol*. 2009 May; 19(3):258-62. [PMID: 19295434](#)

12. Eisenberg ML, Cowan JE, Davies BJ, Carroll PR, Shinohara K. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. *Urol Onc*. 2011;29(2):171-6. Epub 2009 Apr 10. [PMID: 19362864](#)

13. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. *J Urol*. 2009 Nov;182(5):2232-41. [PMID: 19781717](#)

2010

14. Breyer BN, Davis CB, Cowan JE, Kane CJ, Carroll PR. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. *BJU Int*. 2010;106(11):1734-8. [PMID: 20438567](#)

15. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. Adequacy of lymphadenectomy among men undergoing robot assisted laparoscopic radical prostatectomy. *BJU Int*. 2010 Jan;105(1):88-92. [PMID: 19549119](#)

16. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. *Eur Urol*. 2010 Apr;57(4):622-9. Epub 2009 Apr 3. [PMID: 19375843](#)

Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Reply to Piet Ost, Alberto Bossi and Gert De Meerleer's Letter to the Editor. *Eur Urol*. 2010 May 20. [Epub ahead of print] [PMID: 20605674](#)

17. Eisenberg ML, Cowan JE, Carroll PR, Shinohara K. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. *BJU Int*. 2010;105(9):1237-41. [PMID: 19888980](#)

18. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. *Radiology*. 2010 Jul;256(1):176-83. [PMID: 20505068](#)

19. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologic density and county-level urologic cancer mortality. *J Clin Oncol*. 2010 May 20;28(15):2499-504. [PMID: 20406931](#)

20. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumor volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. *BJU Int*. 2010;105(4):472-5. Epub 2009 Aug 13. [PMID: 19681901](#)

21. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. *J Urol*. 2010;184(5):1931-6. [PMID: 20846693](#)

22. Whitson JM, Carroll PR. Active Surveillance for Early-Stage Prostate Cancer: Defining the Triggers for Intervention. *J Clin Oncol*. 2010 Jun 10;28(17):2807-9. [PMID: 20439633](#)

2011

23. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: Always, never, or only sometimes? *J Clin Oncol*. 2011 Feb 1;29(4):345-7. Epub 2010 Dec 28. [PMID: 21189396](#)
24. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll PR. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. *Cancer Causes Control*. 2011 Jan;22(1):141-50. Epub 2010 Nov 20. [PMID: 21103921](#)
25. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate risk prostate cancer. *J Clin Oncol*. 2011 Jan 10;29(2):228-34. Epub 2010 Nov 29. [PMID: 21115873](#)
26. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. *J Urol*. 2011 Jun 14. **[Epub ahead of print]** [PMID: 21679982](#)
27. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. *J Clin Oncol*. 2011 Sep 20;29(27):3669-76. [PMID: 21825257](#)
28. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. *BJU Int*. 2011;107(8):1232-7. Epub 2010 Aug 26. [PMID: 20804478](#)
29. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. *PLoS One*. 2011;6(9):e24004. [PMID: 21912659](#)
30. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; the Canary/Early Detection Research Network Prostate Active Surveillance Study Investigators. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. *J Urol*. 2011;186(2):465-9. [PMID: 21679996](#)
31. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. *J Clin Oncol*. 2011;29(20):2795-800. [PMID: 21632511](#)

32. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. Changes in Cancer Volume in Serial Biopsies of Men on Active Surveillance for Early Stage Prostate Cancer. *J Urol*. 2011;186(5):1825-9. PMID: [21944082](#) This paper will be featured for CME credits.
33. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. *J Urol*. 2011 Dec;186(6):2228-32. PMID: [22014796](#)
34. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. *J Urol*. 2011;185(5):1656-60. PMID: [21419438](#)
35. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. *Urol Onc*. 2011 Apr 7. [Epub ahead of print] PMID: [21478037](#)
36. Whitson JM, Porten SP, Carroll PR. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. *Nat Rev Urol*. 2011 Mar;8(3):124-5. PMID: [21304508](#)
37. Yang G, Whitson JM, Breyer BN, Konety BR, Carroll PR. Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. *Urology*. 2011;77(4):878-83. PMID: [21215428](#)
- 2012**
38. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? *J Clin Oncol*. 2012 Feb 10;30(5):476-8. PMID: [22215744](#)
39. Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. *Eur Urol*. 2012;62(5):753-5. PMID: [22766168](#)
40. Hilton JF, Blaschko SD, Whitson JM, Cowan JE, Carroll PR. The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. *J Urol*. 2012 Oct;188(4):1252-8. PMID: [22902015](#)
41. Jung AJ, Coakley FV, Shinohara K, Carroll PR, Kurhanewicz J, Cowan JE, Westphalen AC. Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound. *Clin Imaging*. 2012 Sep;36(5):547-52. PMID: [22920360](#)

42. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. *Cancer*. 2012;118(24):6046-54. PMID: [22674220](#)

43. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason Score (GS) ≤ 6 have the potential to metastasize to lymph nodes? *Am J Surg Pathol*. 2012;36(9):1346-52. PMID: [22531173](#)

44. Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. *BJU Int*. 2012;110(1):50-5. Epub 2011 Nov 11. PMID: [22077660](#)

2013

45. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. *Adv Anat Pathol*. 2013 Jan;20(1):39-44. PMID: [23232570](#)

In Press

Punnen S, Cowan JE, Carroll PR. How does robot-assisted radical prostatectomy compare to open surgery in men with high-risk prostate cancer? *BJU Int*. 2012. In press.

Related Studies

Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schroder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. *Crit Rev Oncol Hematol*. 2012 Aug 6. [Epub ahead of print] PMID: [22878262](#)

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. *Eur Urol*. 2012 Jun 7. [Epub ahead of print] PMID: [22698574](#)

Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). *J Urol*. 2011 May;185(5):1631-6. [PMID: 21419456](#)

Messing EM, Albertsen P, Andriole GL Jr, Carroll PR, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. *Urol Oncol*. 2012 Jan;30(1):117-9. [PMID: 22243597](#)

Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, Costello A, Eastham JA, Ficarra V, Guazzoni G, Menon M, Novara G, Patel VR, Stolzenburg JU, Van der Poel H, Van Poppel H, Mottrie A. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. *Eur Urol*. 2012 Sep;62(3):368-81. [PMID: 22763081](#)

Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll PR, Coakley FV. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. *AJR Am J Roentgenol*. 2011 Dec;197(6):1369-74. [PMID: 22109291](#)

Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PSA screening: determinants of primary-care physician practice patterns. *Prostate Cancer Prostatic Dis*. 2012;15(2):189-94. Epub 2011 Nov 29. [PMID: 22343837](#)

Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. *Urol Oncol*. 2012 Mar-Apr;30(2):155-60. Epub 2010 Aug 25. [PMID: 20800514](#)

Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. *Prostate Cancer Prostatic Dis*. 2012 Mar;15(1):100-5. Epub 2011 Nov 1. [PMID: 22042252](#)